Various preclinical and clinical studies have revealed that the presence of KRAS activating mutations in CRC correlates with resistance to EGFR monoclonal antibodies (EGFR mAb), such as cetuximab (Erbitax) and panitumumab (Vectibix) (4–8). Here, EGFR is linked to colorectal carcinoma.